Loss of Rassf1a synergizes with deregulated Runx2 signaling in tumorigenesis

Cancer Research

Volumn 72, Issue 15, 2012, Pages 3817-3827

  Van Der Weyden, Louise ^a   Papaspyropoulos, Angelos ^c   Poulogiannis, George ^d   Rust, Alistair G ^a   Rashid, Mamunur ^a   Adams, David J ^a   Arends, Mark J ^b   O'Neill, Eric ^c  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR YAP1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BURKITT LYMPHOMA; CANCER GROWTH; CANCER SURVIVAL; CAPZA1 GENE; CARCINOGENESIS; CLONOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; CREBBP GENE; DOWN REGULATION; FAM193A GENE; FIBROBLAST GROWTH FACTOR RECEPTOR 3 GENE; FOXN3 GENE; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INSERTION; GENE LOSS; GENETIC ASSOCIATION; GENETIC VARIABILITY; LARGE CELL LYMPHOMA; MOLECULAR DYNAMICS; MOUSE; NFIA GENE; NONHUMAN; PPP2R2A GENE; PRIORITY JOURNAL; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A GENE; SIGNAL TRANSDUCTION; STAG2 GENE; STON2 GENE; TEA DOMAIN FAMILY OF TRANSCRIPTION FACTOR GENE; TRANSCRIPTION FACTOR RUNX2 GENE; TRANSCRIPTION FACTOR YAP1 GENE; TRANSPOSON; TUMOR PROMOTION; TUMOR SUPPRESSOR GENE;

EID: 84864829046     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3343     Document Type: Article

References (45)

1. van der Weyden L, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 2007;1776:58-85.
2. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007;120:3163-72.
3. Pan D. The Hippo signaling pathway in development and cancer. Developmental Cell 2010;19:491-505.
4. Wu S, Huang J, Dong J, Pan D. Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 2003;114:445-56.
5. Wei X, Shimizu T, Lai ZC. Mob as tumor suppressor is activated by Hippo kinase for growth inhibition in Drosophila. EMBO J 2007;26:1772-81.
6. Huang J, Wu S, Barrera J, Matthews K, Pan D. The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 2005;122:421-34.
7. Bandura JL, Edgar BA. Yorkie and Scalloped: partners in growth activation. Dev Cell 2008;14:315-6.
8. Zhao B, Ye X, Yu J, Li L, Li W, Li S, et al. TEAD mediates YAPdependent gene induction and growth control. Genes Dev 2008;22:1962-71.
9. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev 2001;15:1229-41.
10. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 2001;276:15164-73.
11. Komuro A, Nagai M, Navin NE, Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003;278:33334-41.
12. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domaincontaining yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999;18:2551-62.
13. Matallanas D, Romano D, Yee K, Meissl K, Kucerova L, Piazzolla D, et al. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell 2007;27:962-75.
14. Hamilton G, Yee KS, Scrace S, O'Neill E. ATM regulates a RASSF1A-dependent DNA damage response. Curr Biol 2009;19:2020-5.
15. van der Weyden L, Tachibana KK, Gonzalez MA, Adams DJ, Ng BL, Petty R, et al. The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol 2005; 25:8356-67.
16. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposonbased somatic mutagenesis in the mouse. Nature 2005;436:272-6.
17. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature 2005;436:221-6.
18. March HN, Rust AG, Wright NA, ten Hoeve J, de Ridder J, Eldridge M, et al. Insertional mutagenesis reveals multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet 2011; 43:1202-9.
19. de Ridder J, Uren A, Kool J, Reinders M, Wessels L. Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput Biol 2006;2:e166.
20. Yee KS, O'Neill E. YAP1-friend and foe. Cell Cycle 2010;9:1447-8.
21. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989;17:6419.
22. Andersen P, Gill R. Cox's regression model for counting processes, a large sample study. Annal Stat 1982;10:1100-20.
23. Hofmann K, Bucher P. The rsp5-domain is shared by proteins of diverse functions. FEBS Lett 1995;358:153-7.
24. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 1997;89:773-9.
25. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 1997;89:755-64.
26. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell 1997;89:765-71.
27. Kool J, Berns A. High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat Rev Cancer 2009;9:389-99.
28. van der Weyden L, Arends MJ, Dovey OM, Harrison HL, Lefebvre G, Conte N, et al. Loss of Rassf1a cooperates with Apc(Min) to accelerate intestinal tumorigenesis. Oncogene 2008;27:4503-8.
29. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat Genet 2000;25:315-9.
30. Busygina V, Kottemann MC, Scott KL, Plon SE, Bale AE. Multiple endocrine neoplasia type 1 interacts with forkhead transcription factor CHES1 in DNA damage response. Cancer Res 2006;66:8397-403.
31. Chen YJ, Liao CT, Chen PJ, Lee LY, Li YC, Chen IH, et al. Down-regulation of Ches1 and other novel genes in oral cancer cells chronically exposed to areca nut extract. Head Neck 2011;33:257-66.
32. Clarke PR, Hoffmann I, Draetta G, Karsenti E. Dephosphorylation of cdc25-C by a type-2A protein phosphatase: specific regulation during the cell cycle in Xenopus egg extracts. Mol Biol Cell 1993;4:397-411.
33. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120:1298-309.
34. Hauf S, Roitinger E, Koch B, Dittrich CM, Mechtler K, Peters JM. Dissociation of cohesin from chromosome arms and loss of arm cohesion during early mitosis depends on phosphorylation of SA2. PLoS Biol 2005;3:e69.
35. Rocquain J, Gelsi-Boyer V, Adélaïde J, Murati A, Carbuccia N, Vey N, et al. Alteration of cohesin genes in myeloid diseases. Am J Hematol 2010;85:717-9.
36. Dickey-Sims C, Robertson AJ, Rupp DE, McCarthy JJ, Coffman JA. Runx-dependent expression of PKC is critical for cell survival in the sea urchin embryo. BMC Biol 2005;3:18-29.
37. Foulds CE, Nelson ML, Blaszczak AG, Graves BJ. Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol Cell Biol 2004;24:10954-64.
38. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, et al. CREBBP mutations in relapsed acute lymphoblastic leukemia. Nature 2011;471:235c9.
39. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010;5:e13821.
40. Al-Ahmadie HA, Iyer G, Janakiraman M, Lin O, Heguy A, Tickoo SK, et al. Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma. J Pathol 2011;224:270-9.
41. Gergen JP, Butler BA. Isolation of the Drosophila segmentation gene runt and analysis of its expression during embryogenesis. Genes Dev 1988;2:1179-93.
42. Thirunavukkarasu K, Mahajan M, McLarren KW, Stifani S, Karsenty G. Two domains unique to osteoblast-speci fic transcription factor Osf2/Cbfa1 contribute to its transactivation function and its inability to heterodimerize with Cbfbeta. Mol Cell Biol 1998;18:4197-208.
43. Blyth K, Cameron ER, Neil JC. The Runx gene family: gain or loss of function in cancer. Nat Rev Cancer 2005;5:376-87.
44. Kilbey A, Blyth K, Wotton S, Terry A, Jenkins A, Bell M, et al. Runx2 disruption promotes immortalization and confers resistance to onco-gene-induced senescence in primary murine fibroblasts. Cancer Res 2007;67:11263-71.
45. Zhang X, George J, Deb S, Degoutin LJ, Takano EA, Fox SB, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 2011;30:2810-22.